European Investor
22 Oct 2026, 15:41
argenx Q3 Sales Jump 54% as VYVGART Momentum and Pipeline Progress Strengthen Growth Outlook
argenx (NASDAQ: ARGX) reported strong third-quarter 2026 growth, with VYVGART continuing to drive rapid commercial expansion while several late-stage pipeline programs moved closer to key regulatory and clinical milestones.
Global product net sales reached $1.7 billion, up 54% year over year and 13% sequentially. Growth was supported by continued adoption of VYVGART across generalized myasthenia gravis and CIDP, with management highlighting further opportunity from geographic expansion and additional indications.
The company is also broadening the VYVGART franchise. An sBLA for ocular myasthenia gravis has been submitted to the FDA, while the pediatric gMG application has been accepted for priority review with a February 2027 PDUFA date. An sBLA for VYVGART Hytrulo in immune-mediated necrotizing myopathy remains on track for submission by year-end 2026 following positive Phase 3 ALKIVIA results.
argenx is also advancing empasiprubart as a second major growth platform. Phase 3 results in multifocal motor neuropathy are expected in December 2026, while additional CIDP readouts are anticipated in the second half of 2027.
Beyond FcRn and empasiprubart, the company is pushing FB102 into Phase 3 development for celiac disease after positive Phase 2 results, positioning the program as another potential long-term growth pillar.
Management reiterated its Vision 2030 ambitions, which include treating 50,000 patients globally, securing 10 labeled indications and moving five pipeline candidates into registrational development by 2030.
Overall, the quarter reinforced argenx’s transition from a single-product biotech into a broader immunology platform, with strong VYVGART growth providing the commercial base while multiple pipeline assets approach potentially important value-creating milestones.
argenx (NASDAQ: ARGX) reported strong third-quarter 2026 growth, with VYVGART continuing to drive rapid commercial expansion while several late-stage pipeline programs moved closer to key regulatory and clinical milestones.
Global product net sales reached $1.7 billion, up 54% year over year and 13% sequentially. Growth was supported by continued adoption of VYVGART across generalized myasthenia gravis and CIDP, with management highlighting further opportunity from geographic expansion and additional indications.
The company is also broadening the VYVGART franchise. An sBLA for ocular myasthenia gravis has been submitted to the FDA, while the pediatric gMG application has been accepted for priority review with a February 2027 PDUFA date. An sBLA for VYVGART Hytrulo in immune-mediated necrotizing myopathy remains on track for submission by year-end 2026 following positive Phase 3 ALKIVIA results.
argenx is also advancing empasiprubart as a second major growth platform. Phase 3 results in multifocal motor neuropathy are expected in December 2026, while additional CIDP readouts are anticipated in the second half of 2027.
Beyond FcRn and empasiprubart, the company is pushing FB102 into Phase 3 development for celiac disease after positive Phase 2 results, positioning the program as another potential long-term growth pillar.
Management reiterated its Vision 2030 ambitions, which include treating 50,000 patients globally, securing 10 labeled indications and moving five pipeline candidates into registrational development by 2030.
Overall, the quarter reinforced argenx’s transition from a single-product biotech into a broader immunology platform, with strong VYVGART growth providing the commercial base while multiple pipeline assets approach potentially important value-creating milestones.
